| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Research and development | $454K+304.1% | $112K-90.2% | $1.1M+17.5% | $978K-51.4% | $2.0M+269.8% | $545K |
| General and administrative | $648K-44.5% | $1.2M-16.8% | $1.4M+50.3% | $934K-42.1% | $1.6M+238.6% | $476K |
| General and administrative affiliates | $740K-21.5% | $943K-24.4% | $1.2M | — | — | — |
| Total operating expenses | $1.8M-17.1% | $2.2M-41.5% | $3.8M+78.1% | $2.1M-49.4% | $4.2M+232.2% | $1.3M |
| Loss from operations | -$1.8M+17.1% | -$2.2M+41.5% | -$3.8M-78.1% | -$2.1M+49.4% | -$4.2M-232.2% | -$1.3M |
| Loss of issuance | $488K | — | -$212K | — | — | — |
| Change in FV of Derivative | -$217K-262.8% | $133K | — | — | — | — |
| Interest expense | -$134K-59.4% | -$84K+56.4% | -$193K+6.7% | -$207K+12.5% | -$237K+76.7% | -$1.0M |
| Interest expense affiliate | -$52K-522.0% | -$8K | — | — | — | — |
| Amortization of Intellectual Property | -$12K-45.2% | -$8K+4.0% | -$8K-127.4% | -$4K | — | — |
| Debt forgiveness | $134K | — | — | — | — | — |
| Debt discount amortization | -$678K | — | -$349K-11.6% | -$312K-305.6% | -$77K+70.3% | -$259K |
| Total other expenses | -$281K-78.8% | -$157K+79.4% | -$763K-45.8% | -$523K-66.8% | -$314K+75.4% | -$1.3M |
| Net loss before provision for income taxes | -$2.1M+10.8% | -$2.4M+47.8% | -$4.6M-71.7% | -$2.7M+41.3% | -$4.5M-78.1% | -$2.5M |
| Net loss | -$2.1M+10.8% | -$2.4M+47.8% | -$4.6M-71.7% | -$2.7M+41.3% | -$4.5M-78.1% | -$2.5M |
| Net loss attributable to the non-controlling interest | $13K | — | $90K-53.3% | $193K-61.0% | $496K+701.7% | $62K |
| NET LOSS ATTRIBUTABLE TO BIOXYTRAN | -$2.1M+10.3% | -$2.4M+47.1% | -$4.5M-81.5% | -$2.5M+38.9% | -$4.0M-62.5% | -$2.5M |
| Loss per common share, basic | -$0.02+0.0% | -$0.02+33.3% | -$0.03-50.0% | -$0.02+50.0% | -$0.04 | — |
| Loss per common share, diluted | -$0.02+0.0% | -$0.02+33.3% | -$0.03-50.0% | -$0.02 | — | — |
| Weighted average number of common shares outstanding, basic | 91.8M-33.7% | 138.6M+3.5% | 134.0M+16.4% | 115.1M+8.4% | 106.3M | — |
| Weighted average number of common shares outstanding, diluted | 91.8M-33.7% | 138.6M+3.5% | 134.0M+16.4% | 115.1M | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.